Neural progenitor cells (NPCs) are potent models of normal and disease neurobiology and cell-based neurological therapy development and testing. NPC solutions from ATCC are a complete system for investigating development, degeneration and regeneration, neurogenetics, neural excitability, nervous system disorders, neurotransmitters, and screening therapeutics. We offer normal and Parkinson’s disease iPSC-derived NPCs. Additionally, we offer gene-edited, lineage specific reporter NPCs. Because we have validated growth and differentiation protocols, ATCC cells are valuable for investigators looking to reduce the time from initial iPSC culture through differentiation to experiment readout, as they eliminate the 4 to 8 weeks for iPSCs to differentiate into NPCs.

ATCC NPCs are derived from a collection of well characterized, integration-free reprogrammed iPSCs. The single donor state of the parental line ensures reduced variation between experiments. Other advantages of ATCC authenticated NPCs include, easy endpoint readout, >80% post-thaw cell viability and post-thaw cell viability >1x106/vial. The cells also exhibit longevity >15 PDLs or 5 passages. The marker expression is Nestin and Pax 6 positive, Tra-I-60 negative. The cells are sterility tested and are negative for bacteria, yeast, fungi, mycoplasma with no viruses detected. The neuronal differentiation potential is >70% Tuj1+ early neurons and >10% dopaminergic neurons.